Evidence map›Paper›PMID 32913995›Full record

ArticleJCO precision oncology2018

Outcomes of Chemotherapy for Microsatellite Instable-High Metastatic Colorectal Cancers.

Katerina Shulman, Ofra Barnett-Griness, Vered Friedman, Joel K Greenson, Stephen B Gruber, Flavio Lejbkowicz, Gad Rennert

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Immunology of Lynch Syndrome.Current oncology reports · 2021
    Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Katerina Shulman, Hillel Yaffe Medical Center, Hadera; , , , , and , Carmel Medical Center, and Technion, Haifa, Israel; , University of Michigan, Ann Arbor, MI; and , University of Southern California, Los Angeles, CA.
Ofra Barnett-Griness, Hillel Yaffe Medical Center, Hadera; , , , , and , Carmel Medical Center, and Technion, Haifa, Israel; , University of Michigan, Ann Arbor, MI; and , University of Southern California, Los Angeles, CA.
Vered Friedman, Hillel Yaffe Medical Center, Hadera; , , , , and , Carmel Medical Center, and Technion, Haifa, Israel; , University of Michigan, Ann Arbor, MI; and , University of Southern California, Los Angeles, CA.
Joel K Greenson, Hillel Yaffe Medical Center, Hadera; , , , , and , Carmel Medical Center, and Technion, Haifa, Israel; , University of Michigan, Ann Arbor, MI; and , University of Southern California, Los Angeles, CA.
Stephen B Gruber, Hillel Yaffe Medical Center, Hadera; , , , , and , Carmel Medical Center, and Technion, Haifa, Israel; , University of Michigan, Ann Arbor, MI; and , University of Southern California, Los Angeles, CA.
Flavio Lejbkowicz, Hillel Yaffe Medical Center, Hadera; , , , , and , Carmel Medical Center, and Technion, Haifa, Israel; , University of Michigan, Ann Arbor, MI; and , University of Southern California, Los Angeles, CA.
Gad Rennert, Hillel Yaffe Medical Center, Hadera; , , , , and , Carmel Medical Center, and Technion, Haifa, Israel; , University of Michigan, Ann Arbor, MI; and , University of Southern California, Los Angeles, CA.
Kathmandu University · NP

Funding

MOLECULAR EPIDEMIOLOGY OF COLORECTAL CANCERR01CA081488 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GRUBER, STEPHEN B · 1999 to 2008
$9.2M
NCI NIH HHS R01 CA081488
6 · The paper itself

Abstract

purposeMicrosatellite instable-high (MSI-H) colorectal cancers (CRCs) are known to carry better survival in the local disease stage even without treatment. The influence of types of treatment on survival of MSI-H metastatic CRCs (mCRCs) is still unclear and is evaluated in this study. MATERIALS AND

methodsPatients with MSI-H mCRC treated with first-line chemotherapy, with or without bevacizumab, identified in the Israeli population-based Molecular Epidemiology of Colorectal Cancer (MECC) study, were diagnosed between 1998 and 2013 and followed up until May 2017; MSI status was determined by comparing 10 markers in tumor and normal tissue. Dates of metastases and death and treatment details were extracted from oncology records.

resultsAmong 590 patients treated for mCRC, 106 (18%) had MSI-H tumors. Patients with MSI-H had a median overall survival (OS, from start of first-line treatment) of 1.6 years. The presence of a somatic B-Raf proto-oncogene (

conclusionClinical outcomes differ substantially between patients with MSS/BRAF-WT mCRC and MSI-H/BRAF-WT mCRC, with measurable differences between chemotherapy regimens. MSI-H mCRCs are a clinically distinct subset of colorectal cancers. Their current poor outcome suggests that new clinical trials are needed to identify therapeutic options, potentially taking advantage of the new developments in the field of immunotherapy.

Identifiers

PMID32913995
PMCPMC7446482
OpenAlexW2884353653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.